Abbott Laboratories stock (US0028241000): Kepler Cheuvreux Suisse buys new stake

Kepler Cheuvreux Suisse SA established a new position in Abbott Laboratories (NYSE:ABT) shares during Q4, per recent SEC filing. This comes amid positive analyst sentiment and strong medical device growth reported for Q1.

Kepler Cheuvreux Suisse SA acquired a new stake in Abbott Laboratories during the fourth quarter, according to a MarketBeat report as of May 11, 2026. The move highlights institutional interest in the healthcare giant, which listed on NYSE under ticker ABT. Abbott also showed quarterly revenue growth of 7.8% year-over-year, with its Medical Devices segment posting 8.5% growth in Q1 driven by electrophysiology and rhythm management products.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Abbott Laboratories
• Sector/industry: Healthcare / Medical Devices & Diagnostics
• Headquarters/country: United States
• Core markets: US, Europe, Asia
• Key revenue drivers: Diagnostics, Medical Devices, Nutrition, Pharmaceuticals
• Home exchange/listing venue: NYSE (ABT)
• Trading currency: USD

Abbott Laboratories: core business model

Abbott Laboratories operates as a diversified healthcare company focused on diagnostics, medical devices, nutritional products, and established pharmaceuticals. The firm generates revenue across four main segments, with a strong emphasis on innovation in high-growth areas like diabetes care and cardiovascular devices. Its business model relies on global distribution, R&D investment, and strategic acquisitions to maintain market leadership, particularly relevant for US investors due to its NYSE listing and significant exposure to the American healthcare market.

Abbott's diagnostics division, including tests for COVID-19 and other infectious diseases, has been a key performer, while medical devices cover structural heart and neuromodulation technologies. The company reported a return on equity of 17.62% and net margin of 13.90% in recent filings, underscoring operational efficiency as of data published with Q4 results.

Main revenue and product drivers for Abbott Laboratories

Abbott's top revenue drivers include its Medical Devices segment, which grew 8.5% in Q1 2026, fueled by electrophysiology, rhythm management, and heart failure products, per MarketBeat as of May 11, 2026. Nutrition and diagnostics also contribute significantly, with quarterly revenue up 7.8% year-over-year. Key products like FreeStyle Libre for continuous glucose monitoring drive diabetes care sales, a critical area for US patients amid rising prevalence.

Established pharmaceuticals provide steady cash flow, while recent earnings showed EPS of $1.15 for a quarter, beating consensus by $0.01 with revenue at $11.16 billion, according to MarketBeat as of May 11, 2026. These metrics highlight resilience in core markets.

Industry trends and competitive position

The medical devices sector is expanding due to aging populations and technological advances in minimally invasive procedures, positioning Abbott favorably against peers like Medtronic and Boston Scientific. Abbott's focus on electrophysiology aligns with rising demand for arrhythmia treatments in the US, where cardiovascular disease affects millions. Wall Street maintains a bullish outlook, with Wells Fargo reaffirming a Buy rating recently, supporting long-term growth potential.

Why Abbott Laboratories matters for US investors

As a NYSE-listed blue-chip stock, Abbott Laboratories offers US investors exposure to essential healthcare sectors with defensive qualities. Its products serve the vast US market, including Medicare-covered diagnostics and devices, tying performance to American economic and demographic trends. Institutional moves like Kepler Cheuvreux's new stake signal confidence amid market volatility.

Conclusion

Abbott Laboratories continues to demonstrate strength in medical devices and diagnostics, bolstered by new institutional investment from Kepler Cheuvreux Suisse SA and positive analyst reaffirmations like Wells Fargo's Buy rating. While recent share underperformance versus the market persists, robust segment growth and a payout ratio of 70.59% provide a balanced profile. Investors track upcoming catalysts in its innovation pipeline.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.